TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27247869

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 50
Study: 24553426

Group type: EXPERIMENTAL
Intervention: Regular drinkers (mild, moderate, heavy)
Number of subjects: 3542

Group type: COMPARATOR
Intervention: Abstainers and irregular drinkers
Number of subjects: 3542

Group type: EXPERIMENTAL
Intervention: rs1229984 G→A polymorphism
Number of subjects: 3542
Study: 22374410

Group type: EXPERIMENTAL
Intervention: Electronic resource use (mean of 20.3 days in the past 365 days)
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Residency teaching clinics
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Hospital inpatient practices
Number of subjects: 3958

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3958
Study: 20932293

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team training in a medical simulation centre
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Control arm without any team training
Number of subjects: 4800
Study: 17706223

Group type: EXPERIMENTAL
Intervention: IL-10 concentration >= 1.04 pg/mL
Number of subjects: 71

Group type: COMPARATOR
Intervention: IL-10 concentration < 1.04 pg/mL
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: One standard deviation increase in baseline IL-10 concentration
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: IL-10 concentration in diabetics
Number of subjects: 71
Study: 15735461

Group type: EXPERIMENTAL
Intervention: Hand/rotary/ultrasound technique (1 min of ultrasonic irrigation)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hand/rotary technique
Number of subjects: 31

Group type: COMPARATOR
Intervention: Histologic controls (5 uninstrumented mandibular molars)
Number of subjects: 31
Study: 15189605

Group type: EXPERIMENTAL
Intervention: Observed behaviors during dyadic interactions
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Dominant behavior
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Friendly behavior
Number of subjects: 158
Study: 10585065

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (mitomycin C 10 mg/m2, vinblastine 6 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 57
Study: 8913128

Group type: EXPERIMENTAL
Intervention: Flashlight test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Van Herick's test
Number of subjects: 96

Group type: COMPARATOR
Intervention: Gonioscopy (gold standard)
Number of subjects: 96
Study: 1830257

Group type: EXPERIMENTAL
Intervention: Education programme under the guidance of a health care professional
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Education programme under the guidance of a fellow patient
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 558
Study: 6338164

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone phosphate (100 mg administered within 6 hours of the accident)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 30901053

Group type: COMPARATOR
Intervention: No financial incentive
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Unconditional $10 incentive
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Conditional $10 incentive
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Conditional lottery with a 1-in-10 chance of winning $100
Number of subjects: 897
Study: 29953476

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (X)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (XELOX)
Number of subjects: 0
Study: 28134601

Group type: EXPERIMENTAL
Intervention: Natix alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bio-Oss plus collagen membrane
Number of subjects: 24
Study: 25082832

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: E-cigarette use among current smokers
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: E-cigarette use among never-smokers
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: E-cigarette use among ex-smokers
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Change in smoking habits among regular e-cigarette users
Number of subjects: 3000
Study: 22781792

Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +4
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +7
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without TPO (Group A)
Number of subjects: 120
Study: 20193551

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (P group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP group)
Number of subjects: 80
Study: 17483009

Group type: EXPERIMENTAL
Intervention: Applephenon (1200 mg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1000 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15156310

Group type: EXPERIMENTAL
Intervention: Elastic stable intramedullary nailing (ESIN)
Number of subjects: 112
Study: 11593916

Group type: EXPERIMENTAL
Intervention: Naproxen 10 mg/kg BW bid for 2 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo and paracetamol as needed
Number of subjects: 18
Study: 9589685

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day, orally for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GnRH analog (one ampule every 28 days for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GnRH analog plus naltrexone (for 2 months)
Number of subjects: 40
Study: 8059817

Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening (two screening sonograms at 15 to 22 weeks and 31 to 35 weeks)
Number of subjects: 15281

Group type: COMPARATOR
Intervention: Conventional obstetric care (ultrasonography used only as determined by clinical judgment)
Number of subjects: 15281

Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening
Number of subjects: 15281

Group type: COMPARATOR
Intervention: Conventional obstetric care
Number of subjects: 15281
Study: 2929297

Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 68

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 68
Study: 30944985

Group type: EXPERIMENTAL
Intervention: Relaxation-guided imagery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 26658899

Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 g dextrose + 8 g CM
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (8 g dextrose)
Number of subjects: 15
Study: 24213780

Group type: EXPERIMENTAL
Intervention: Education session plus motivational interview and two self-regulation coaching sessions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (group-based patient education session led by a physical therapist)
Number of subjects: 78
Study: 22451347

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (20 mg, 2 tablets per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (20 mg, 1 tablet per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (1000 and 3000 mg/kg) in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (various doses) in rats
Number of subjects: 0
Study: 21321292

Group type: EXPERIMENTAL
Intervention: Fludarabine plus rituximab
Number of subjects: 104
Study: 18801781

Group type: EXPERIMENTAL
Intervention: CHOICE programme (n = 72)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (n = 72)
Number of subjects: 144
Study: 17081623

Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4(+) CD45R0(+) CD26(high) memory T lymphocytes
Number of subjects: 0
Study: 14996484

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 35
Study: 11518042

Group type: EXPERIMENTAL
Intervention: Intensive 3-week inpatient rehabilitation course
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (18 consecutive SpA patients)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3-year follow-up for study patients
Number of subjects: 25
Study: 9489643

Group type: EXPERIMENTAL
Intervention: PBPC infusion over 1 day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBPC infusion over 2 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBPC infusion over 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBPC infusion as a single infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: PBPC infusion over 1, 2 or 3 days
Number of subjects: 60
Study: 8165854

Group type: EXPERIMENTAL
Intervention: Four-dose schedule (40 micrograms each at 0, 1, 2, and 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dose schedule (40 micrograms each at 0, 1, and 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-dose schedule (half the amount of vaccine) in healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four-dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-dose schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-dose schedule in healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four-dose and three-dose schedules
Number of subjects: 0
Study: 3073355

Group type: EXPERIMENTAL
Intervention: TISACID (Al-Mg-hydroxy-carbonate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TISACID (Al-Mg-hydroxy-carbonate) with cimetidine
Number of subjects: 0
Study: 31652554

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU/day)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 29637322

Group type: EXPERIMENTAL
Intervention: Early education treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive early educational treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis
Number of subjects: 0
Study: 27196675

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + ribavirin (RBV)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: sofosbuvir (SOF) + ribavirin (RBV)
Number of subjects: 493
Study: 24981505

Group type: EXPERIMENTAL
Intervention: Home based HIV testing and counseling (HTC) intervention
Number of subjects: 0
Study: 22162542

Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours from day 8 through day 23
Number of subjects: 24
Study: 19935778

Group type: EXPERIMENTAL
Intervention: TD101 (siRNA)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1
Study: 17397308

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate chip (CHIP group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP group)
Number of subjects: 42
Study: 15759167

Group type: EXPERIMENTAL
Intervention: Specific Language Impairment (SLI) children
Number of subjects: 138

Group type: COMPARATOR
Intervention: Language Impairment (LI) children
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Auditory short-term memory assessment
Number of subjects: 138
Study: 12222545

Group type: EXPERIMENTAL
Intervention: 30-gauge, 5/16-inch insulin syringe
Number of subjects: 124

Group type: COMPARATOR
Intervention: 26-gauge, 3/8-inch tuberculin syringe
Number of subjects: 124
Study: 10520785

Group type: EXPERIMENTAL
Intervention: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) after DCA
Number of subjects: 225

Group type: COMPARATOR
Intervention: Stand-alone DCA
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Adjunctive PTCA
Number of subjects: 225

Group type: COMPARATOR
Intervention: DCA alone
Number of subjects: 225
Study: 7486603

Group type: EXPERIMENTAL
Intervention: 30-mg dose of nimodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60-mg dose of nimodipine
Number of subjects: 12
Study: 2138490

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-fentanyl-thiopentone anaesthesia (BAL group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-halothane anaesthesia (HAL group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mivacurium chloride (various doses)
Number of subjects: 72
Study: 7328681

Group type: EXPERIMENTAL
Intervention: Sex therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Communication therapy
Number of subjects: 48
Study: 30302786

Group type: EXPERIMENTAL
Intervention: Risdiplam (0.6-18.0 mg, n=18)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Itraconazole (n=8)
Number of subjects: 25
Study: 28675594

Group type: COMPARATOR
Intervention: Single-dose letermovir (120, 240, 480, 720, and 960 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multiple-dose letermovir (240 mg, once-daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24950277

Group type: EXPERIMENTAL
Intervention: Simultaneous phlebectomy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Delayed varicosity treatment
Number of subjects: 101
Study: 24495792

Group type: EXPERIMENTAL
Intervention: Telmisartan plus rosuvastatin (combination group)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Telmisartan (group)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (group)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 22814578

Group type: EXPERIMENTAL
Intervention: Pyridoxine (50 mg po three times daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 20575722

Group type: EXPERIMENTAL
Intervention: Telemedicine (store-and-forward)
Number of subjects: 3000
Study: 17927554

Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anger) with experiential suppression
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anxiety) with expressive suppression
Number of subjects: 187

Group type: COMPARATOR
Intervention: Emotion-Induction (anger) with nonsuppression
Number of subjects: 187

Group type: COMPARATOR
Intervention: Emotion-Induction (anxiety) with nonsuppression
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anger) with expressive suppression
Number of subjects: 187

Group type: COMPARATOR
Intervention: Emotion-Induction (anxiety) with experiential suppression
Number of subjects: 187
Study: 16371925

Group type: EXPERIMENTAL
Intervention: High dose (two capsules of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low dose (one capsule of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low dose (one capsule of Oxy-Q)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High dose (two capsules of Oxy-Q)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (placebo) and Low dose (one capsule of Oxy-Q)
Number of subjects: 43
Study: 12669769

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of rifampicin, isoniazid, and pyrazinamid (Trifazid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Separate administration of rifampicin, isoniazid, and pyrazinamid
Number of subjects: 16
Study: 9825266

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 0
Study: 7917561

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus nadolol (mean final dose: 82 +/- 31 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus nadolol
Number of subjects: 40
Study: 2560548

Group type: COMPARATOR
Intervention: 0% delta 9‐THC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.3% delta 9‐THC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.7% delta 9‐THC
Number of subjects: 12
Study: 380184

Group type: EXPERIMENTAL
Intervention: iopronic acid (4.5 g Oravue, Squibb)
Number of subjects: 98

Group type: COMPARATOR
Intervention: iopanoic acid (3 g Telepaque, Winthrop)
Number of subjects: 98
Study: 30782258

Group type: EXPERIMENTAL
Intervention: 150 mg moclobemide tablets (Jelfa)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 150 mg Aurorix tablets (Hoffmann la Roche)
Number of subjects: 10
Study: 29109107

Group type: EXPERIMENTAL
Intervention: Web site with vaccine information and interactive social media components (VSM)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Web site with vaccine information (VI)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 888
Study: 26196188

Group type: EXPERIMENTAL
Intervention: Immediate switch to paliperidone palmitate
Number of subjects: 154

Group type: COMPARATOR
Intervention: Delayed switch to paliperidone palmitate
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 23981400

Group type: EXPERIMENTAL
Intervention: Acupressure using a TENS acupressure apparatus applied at SP6, ST36, SP10, and LI11 points, three times per week for 6 weeks (total of 18 sessions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group received no acupressure
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 78
Study: 21856226

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 846

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 846
Study: 19426108

Group type: EXPERIMENTAL
Intervention: Thrombin solution (100 unit/ml) irrigation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline solution irrigation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline solution irrigation with anti-platelet medication
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Thrombin solution irrigation with anti-platelet medication
Number of subjects: 79
Study: 18945220

Group type: EXPERIMENTAL
Intervention: 15-minute counseling visit with AUDIT screening and health promotion booklet discussion (experimental group)
Number of subjects: 275

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 275
Study: 15051194

Group type: EXPERIMENTAL
Intervention: Noncycloplegic retinoscopy (NCR)
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Retinomax Autorefractor
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: SureSight Vision Screener
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Lea Symbols test
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Power Refractor II
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: HOTV VA test
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Random Dot E stereoacuity
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Stereo Smile II
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Cover-uncover test
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: MTI photoscreener
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: iScreen photoscreener
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: NCR, Retinomax Autorefractor, Lea Symbols VA test
Number of subjects: 2588
Study: 12188988

Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Number of subjects: 120

Group type: COMPARATOR
Intervention: Information package
Number of subjects: 120
Study: 9719164

Group type: EXPERIMENTAL
Intervention: 20% albumin infusion 100 ml three times per week for 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no albumin infusion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Four weeks after withdrawal of albumin infusion
Number of subjects: 22
Study: 7661351

Group type: EXPERIMENTAL
Intervention: Trachlight
Number of subjects: 950

Group type: COMPARATOR
Intervention: Laryngoscope
Number of subjects: 950
Study: 2673623

Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg t.i.d.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tranylcypromine 10 mg b.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1273208

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.25 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 5
Study: 11294464

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 706

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Propofol and Methohexital
Number of subjects: 706
Study: 31354513

Group type: EXPERIMENTAL
Intervention: Whole-body vibration group (WBVG)
Number of subjects: 38
Study: 29020329

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VITD3) 50000 IU monthly plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Number of subjects: 214
Study: 26857941

Group type: EXPERIMENTAL
Intervention: Team competition environment (n = 200)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group (n = 222)
Number of subjects: 422
Study: 23955924

Group type: EXPERIMENTAL
Intervention: Stress and Adversity Inventory (STRAIN) coupled with a related lecture and discussion
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Stress and Adversity Inventory (STRAIN) paired with a general stress lecture
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: STRAIN-specific lecture
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 164
Study: 21290113

Group type: COMPARATOR
Intervention: Irradiated hamstring tendon allograft (Ir‐Allo)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Non‐irradiated hamstring tendon allograft (Non‐ir‐Allo)
Number of subjects: 78